

Senate Bill 749

Sponsored by Senator BOQUIST (at the request of Jill Payne)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Requires health benefit plans to cover fertility and reproductive endocrinology services.

A BILL FOR AN ACT

1
2 Relating to insurance coverage of reproductive health services; creating new provisions; and
3 amending ORS 414.432 and 743A.067.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1.** ORS 743A.067 is amended to read:

6 743A.067. (1) As used in this section:

7 (a) "Contraceptives" means health care services, drugs, devices, products or medical procedures
8 to prevent a pregnancy.

9 (b) "Enrollee" means an insured individual and the individual's spouse, domestic partner and
10 dependents who are beneficiaries under the insured individual's health benefit plan.

11 (c) "Health benefit plan" has the meaning given that term in ORS 743B.005, excluding Medicare
12 Advantage Plans and including health benefit plans offering pharmacy benefits administered by a
13 third party administrator or pharmacy benefit manager.

14 (d) "Religious employer" has the meaning given that term in ORS 743A.066.

15 (2) A health benefit plan offered in this state must provide coverage for all of the following
16 services, drugs, devices, products and procedures:

17 (a) Well-woman care prescribed by the Department of Consumer and Business Services by rule
18 consistent with guidelines published by the United States Health Resources and Services Adminis-
19 tration.

20 **(b) Fertility and reproductive endocrinology services for men or women.**

21 *[(b)]* **(c)** Counseling for sexually transmitted infections, including but not limited to human
22 immunodeficiency virus and acquired immune deficiency syndrome.

23 *[(c)]* **(d)** Screening for:

24 (A) Chlamydia;

25 (B) Gonorrhea;

26 (C) Hepatitis B;

27 (D) Hepatitis C;

28 (E) Human immunodeficiency virus and acquired immune deficiency syndrome;

29 (F) Human papillomavirus;

30 (G) Syphilis;

31 (H) Anemia;

32 (I) Urinary tract infection;

NOTE: Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.

- 1 (J) Pregnancy;
- 2 (K) Rh incompatibility;
- 3 (L) Gestational diabetes;
- 4 (M) Osteoporosis;
- 5 (N) Breast cancer; and
- 6 (O) Cervical cancer.

7 [(d)] (e) Screening to determine whether counseling related to the BRCA1 or BRCA2 genetic
8 mutations is indicated and counseling related to the BRCA1 or BRCA2 genetic mutations if indi-
9 cated.

10 [(e)] (f) Screening and appropriate counseling or interventions for:

- 11 (A) Tobacco use; and
- 12 (B) Domestic and interpersonal violence.

13 [(f)] (g) Folic acid supplements.

14 [(g)] (h) Abortion.

15 [(h)] (i) Breastfeeding comprehensive support, counseling and supplies.

16 [(i)] (j) Breast cancer chemoprevention counseling.

17 [(j)] (k) Any contraceptive drug, device or product approved by the United States Food and Drug
18 Administration, subject to all of the following:

19 (A) If there is a therapeutic equivalent of a contraceptive drug, device or product approved by
20 the United States Food and Drug Administration, a health benefit plan may provide coverage for
21 either the requested contraceptive drug, device or product or for one or more therapeutic equiv-
22 alents of the requested drug, device or product.

23 (B) If a contraceptive drug, device or product covered by the health benefit plan is deemed
24 medically inadvisable by the enrollee's provider, the health benefit plan must cover an alternative
25 contraceptive drug, device or product prescribed by the provider.

26 (C) A health benefit plan must pay pharmacy claims for reimbursement of all contraceptive
27 drugs available for over-the-counter sale that are approved by the United States Food and Drug
28 Administration.

29 (D) A health benefit plan may not infringe upon an enrollee's choice of contraceptive drug, de-
30 vice or product and may not require prior authorization, step therapy or other utilization control
31 techniques for medically appropriate covered contraceptive drugs, devices or other products ap-
32 proved by the United States Food and Drug Administration.

33 [(k)] (L) Voluntary sterilization.

34 [(L)] (m) As a single claim or combined with other claims for covered services provided on the
35 same day:

36 (A) Patient education and counseling on contraception and sterilization.

37 (B) Services related to sterilization or the administration and monitoring of contraceptive drugs,
38 devices and products, including but not limited to:

39 (i) Management of side effects;

40 (ii) Counseling for continued adherence to a prescribed regimen;

41 (iii) Device insertion and removal; and

42 (iv) Provision of alternative contraceptive drugs, devices or products deemed medically appro-
43 priate in the judgment of the enrollee's provider.

44 [(m)] (n) Any additional preventive services for women that must be covered without cost
45 sharing under 42 U.S.C. 300gg-13, as identified by the United States Preventive Services Task Force

1 or the Health Resources and Services Administration of the United States Department of Health and
2 Human Services as of January 1, 2017.

3 (3) A health benefit plan may not impose on an enrollee a deductible, coinsurance, copayment
4 or any other cost-sharing requirement on the coverage required by this section. A health care pro-
5 vider shall be reimbursed for providing the services described in this section without any deduction
6 for coinsurance, copayments or any other cost-sharing amounts.

7 (4) Except as authorized under this section, a health benefit plan may not impose any re-
8 strictions or delays on the coverage required by this section.

9 (5) This section does not exclude coverage for contraceptive drugs, devices or products pre-
10 scribed by a provider, acting within the provider's scope of practice, for:

11 (a) Reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer
12 or eliminating symptoms of menopause; or

13 (b) Contraception that is necessary to preserve the life or health of an enrollee.

14 (6) This section does not limit the authority of the Department of Consumer and Business Ser-
15 vices to ensure compliance with ORS 743A.063 and 743A.066.

16 (7) This section does not require a health benefit plan to cover:

17 (a) Experimental or investigational treatments;

18 (b) Clinical trials or demonstration projects, except as provided in ORS 743A.192;

19 (c) Treatments that do not conform to acceptable and customary standards of medical practice;

20 (d) Treatments for which there is insufficient data to determine efficacy; or

21 (e) Abortion if the insurer offering the health benefit plan excluded coverage for abortion in all
22 of its individual, small employer and large employer group plans during the 2017 plan year.

23 (8) If services, drugs, devices, products or procedures required by this section are provided by
24 an out-of-network provider, the health benefit plan must cover the services, drugs, devices, products
25 or procedures without imposing any cost-sharing requirement on the enrollee if:

26 (a) There is no in-network provider to furnish the service, drug, device, product or procedure
27 that is geographically accessible or accessible in a reasonable amount of time, as defined by the
28 Department of Consumer and Business Services by rule consistent with the requirements for pro-
29 vider networks in ORS 743B.505; or

30 (b) An in-network provider is unable or unwilling to provide the service in a timely manner.

31 (9) An insurer may offer to a religious employer a health benefit plan that does not include
32 coverage for contraceptives or abortion procedures that are contrary to the religious employer's
33 religious tenets only if the insurer notifies in writing all employees who may be enrolled in the
34 health benefit plan of the contraceptives and procedures the employer refuses to cover for religious
35 reasons.

36 (10) If the Department of Consumer and Business Services concludes that enforcement of this
37 section may adversely affect the allocation of federal funds to this state, the department may grant
38 an exemption to the requirements but only to the minimum extent necessary to ensure the continued
39 receipt of federal funds.

40 (11) An insurer that is subject to this section shall make readily accessible to enrollees and
41 potential enrollees, in a consumer-friendly format, information about the coverage of contraceptives
42 by each health benefit plan and the coverage of other services, drugs, devices, products and proce-
43 dures described in this section. The insurer must provide the information:

44 (a) On the insurer's website; and

45 (b) In writing upon request by an enrollee or potential enrollee.

1 (12) This section does not prohibit an insurer from using reasonable medical management tech-
 2 niques to determine the frequency, method, treatment or setting for the coverage of services, drugs,
 3 devices, products and procedures described in subsection (2) of this section, other than coverage
 4 required by subsection [(2)(g) and (j)] **(2)(h) and (k)** of this section, if the techniques:

- 5 (a) Are consistent with the coverage requirements of subsection (2) of this section; and
- 6 (b) Do not result in the wholesale or indiscriminate denial of coverage for a service.

7 **SECTION 2.** ORS 414.432 is amended to read:

8 414.432. (1) The Oregon Health Authority shall administer a program to reimburse the cost of
 9 medically appropriate services, drugs, devices, products and procedures described in ORS 743A.067
 10 **(2)(a) and (c) to (n)**, for individuals who can become pregnant and who would be eligible for med-
 11 ical assistance if not for 8 U.S.C. 1611 or 1612.

12 (2) The authority shall provide the medical assistance for pregnant women that is authorized
 13 by Title XXI, section 2112, of the Social Security Act (42 U.S.C. 13971l) for 60 days immediately
 14 postpartum.

15 (3) The authority shall collect data and analyze the cost-effectiveness of the services, drugs,
 16 devices, products and procedures paid for under this section.

17 (4) The authority, in collaboration with the Department of Consumer and Business Services if
 18 necessary, shall explore any and all opportunities to obtain federal financial participation in the
 19 costs of implementing this section, including but not limited to waivers or demonstration projects
 20 under Title X of the Public Health Service Act or Title XIX or XXI of the Social Security Act.
 21 However, the implementation of this section is not contingent upon the authority's receipt of a
 22 waiver or authorization to operate a demonstration project.

23 **SECTION 3. The amendments to ORS 743A.067 by section 1 of this 2019 Act apply to**
 24 **health benefit plans issued, renewed or extended on or after the effective date of this 2019**
 25 **Act.**

26 _____